Literature DB >> 16533714

Selective optimization of side activities: the SOSA approach.

Camille G Wermuth1.   

Abstract

Selective optimization of side activities of drug molecules (the SOSA approach) is an intelligent and potentially more efficient strategy than HTS for the generation of new biological activities. Only a limited number of highly diverse drug molecules are screened, for which bioavailability and toxicity studies have already been performed and efficacy in humans has been confirmed. Once the screening has generated a hit it will be used as the starting point for a drug discovery program. Using traditional medicinal chemistry as well as parallel synthesis, the initial 'side activity' is transformed into the 'main activity' and, conversely, the initial 'main activity' is significantly reduced or abolished. This strategy has a high probability of yielding safe, bioavailable, original and patentable analogues.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16533714     DOI: 10.1016/S1359-6446(05)03686-X

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  36 in total

1.  Computer-Aided Selective Optimization of Side Activities of Talinolol.

Authors:  Kerstin Hiesinger; Jan S Kramer; Janosch Achenbach; Daniel Moser; Julia Weber; Sandra K Wittmann; Christophe Morisseau; Carlo Angioni; Gerd Geisslinger; Astrid S Kahnt; Astrid Kaiser; Anna Proschak; Dieter Steinhilber; Denys Pogoryelov; Karen Wagner; Bruce D Hammock; Ewgenij Proschak
Journal:  ACS Med Chem Lett       Date:  2019-05-29       Impact factor: 4.345

2.  Prediction and evaluation of protein farnesyltransferase inhibition by commercial drugs.

Authors:  Amanda J DeGraw; Michael J Keiser; Joshua D Ochocki; Brian K Shoichet; Mark D Distefano
Journal:  J Med Chem       Date:  2010-03-25       Impact factor: 7.446

Review 3.  Structure and dynamics of molecular networks: a novel paradigm of drug discovery: a comprehensive review.

Authors:  Peter Csermely; Tamás Korcsmáros; Huba J M Kiss; Gábor London; Ruth Nussinov
Journal:  Pharmacol Ther       Date:  2013-02-04       Impact factor: 12.310

4.  Drug discovery: follow your lead.

Authors:  Brian K Shoichet
Journal:  Nat Chem Biol       Date:  2014-04       Impact factor: 15.040

5.  Discovery and Characterization of 2-Aminooxazolines as Highly Potent, Selective, and Orally Active TAAR1 Agonists.

Authors:  Guido Galley; Angélica Beurier; Guillaume Décoret; Annick Goergler; Roman Hutter; Susanne Mohr; Axel Pähler; Philipp Schmid; Dietrich Türck; Robert Unger; Katrin Groebke Zbinden; Marius C Hoener; Roger D Norcross
Journal:  ACS Med Chem Lett       Date:  2015-12-30       Impact factor: 4.345

6.  Immunohistochemical Analysis of the Stem Cell Marker LGR5 in Pediatric Liver Disease.

Authors:  Zahida Khan; Anne Orr; George K Michalopoulos; Sarangarajan Ranganathan
Journal:  Pediatr Dev Pathol       Date:  2017 Jan-Feb

7.  Adenylate kinase release as a high-throughput-screening-compatible reporter of bacterial lysis for identification of antibacterial agents.

Authors:  Anna C Jacobs; Louis Didone; Jennielle Jobson; Madeline K Sofia; Damian Krysan; Paul M Dunman
Journal:  Antimicrob Agents Chemother       Date:  2012-10-01       Impact factor: 5.191

8.  Derivatives of the Antimalarial Drug Mefloquine Are Broad-Spectrum Antifungal Molecules with Activity against Drug-Resistant Clinical Isolates.

Authors:  Marhiah C Montoya; Sarah Beattie; Kathryn M Alden; Damian J Krysan
Journal:  Antimicrob Agents Chemother       Date:  2020-02-21       Impact factor: 5.191

9.  New life for an old drug: the anthelmintic drug niclosamide inhibits Pseudomonas aeruginosa quorum sensing.

Authors:  Francesco Imperi; Francesco Massai; Cejoice Ramachandran Pillai; Francesca Longo; Elisabetta Zennaro; Giordano Rampioni; Paolo Visca; Livia Leoni
Journal:  Antimicrob Agents Chemother       Date:  2012-12-17       Impact factor: 5.191

10.  Limitations in a frataxin knockdown cell model for Friedreich ataxia in a high-throughput drug screen.

Authors:  Nadège Calmels; Hervé Seznec; Pascal Villa; Laurence Reutenauer; Marcel Hibert; Jacques Haiech; Pierre Rustin; Michel Koenig; Hélène Puccio
Journal:  BMC Neurol       Date:  2009-08-24       Impact factor: 2.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.